Ketamine for Mood Disorders With Suicidal Ideation
NCT04099771 · The Miriam Hospital
What it is testing
Summary
Summary as written by the trial’s own sponsor and published on ClinicalTrials.gov API v2. It is the sponsor’s description, reproduced unedited, not an assessment by this site.
What counts as success
Primary outcome measures
Number and Rate of Participants Recruited into the Study throughout study period
Measured over One year
Completion of total infusion of ketamine by participants
Measured over One year
Percentage of participants and providers with positive response to ketamine administration
Measured over One year
A trial succeeds or fails on its primary outcome, declared in advance. Everything else it reports is secondary by definition.
Who can take part
Eligibility, as published
Where
1 study site
| Facility | City | Region | Country |
|---|---|---|---|
| The Miriam Hospital | Providence | Rhode Island | United States |
On the registry
Contact the trial directly
This site does not enrol anyone and is not involved in this trial. To ask about taking part, use the sponsor’s own contact details on the official registry record, which is also where the most current version of everything above lives.
Before you do, the preparation checklist lists what a site will ask you on a first call and what is worth asking them. It is free and collects nothing.
NCT04099771 on ClinicalTrials.gov →
Last updated in the registry 2021-03-02. Registry records change; this page reflects the data build of 2026-08-25.
Related
Where this trial sits
Substance
Recruiting in